A decade ago, just five drugs were licensed for the treatment of viral infections. Since then,
greater understanding of viral life cycles, prompted in particular by the need to combat …

Since the discovery of the human immunodeficiency virus (HIV) in 1983, dramatic progress
has been made in the development of novel antiviral drugs. The HIV epidemic fuelled the …

Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with
more than 170 million infected individuals at risk of developing significant morbidity and …

In recent years, the demand for new antiviral strategies has increased markedly. There are
many contributing factors to this increased demand, including the ever-increasing …

Hepatitis C virus (HCV) is among the most relevant causes of liver cirrhosis and
hepatocellular carcinoma. Research is complicated by a lack of accessible small animal …

Recent advances in reverse genetics of hepatitis C virus (HCV) made it possible to
determine the properties and biochemical compositions of HCV virions. Sedimentation …

Nearly 200 million individuals worldwide are currently infected with hepatitis C virus (HCV).
Combination therapy with pegylated interferon and ribavirin, the latest treatment for HCV …

Hepatitis C virus (HCV) RNA replication depends on viral protein association with
intracellular membranes, but the influence of membrane composition on viral replication is …

Highly conserved noncoding RNA (ncRNA) elements in viral genomes and transcripts offer
new opportunities to expand the repertoire of drug targets for the development of …

C. Proteolytic Processing of Structural Proteins D. Proteolytic Processing of Nonstructural
Proteins E. Cis-Acting RNA Sequences Required for Replication F. Mechanism of RNA …